TY - JOUR
T1 - Parental Attitudes Toward Standard Newborn Screening and Newborn Genomic Sequencing
T2 - Findings From the BabySeq Study
AU - The BabySeq Project Team
AU - Armstrong, Brittan
AU - Christensen, Kurt D.
AU - Genetti, Casie A.
AU - Parad, Richard B.
AU - Robinson, Jill Oliver
AU - Blout Zawatsky, Carrie L.
AU - Zettler, Bethany
AU - Beggs, Alan H.
AU - Holm, Ingrid A.
AU - Green, Robert C.
AU - McGuire, Amy L.
AU - Smith, Hadley Stevens
AU - Pereira, Stacey
AU - Agrawal, Pankaj B.
AU - Betting, Wendi N.
AU - Ceyhan-Birsoy, Ozge
AU - Dukhovny, Dmitry
AU - Fayer, Shawn
AU - Frankel, Leslie A.
AU - Graham, Chet
AU - Gutierrez, Amanda M.
AU - Harden, Maegan
AU - Krier, Joel B.
AU - Lebo, Matthew S.
AU - Lee, Kaitlyn B.
AU - Levy, Harvey L.
AU - Lu, Xingquan
AU - Machini, Kalotina
AU - McGuire, Amy L.
AU - Murry, Jaclyn B.
AU - Naik, Medha
AU - Nguyen Dolphyn, Tiffany T.
AU - Peoples, Hayley A.
AU - Petersen, Devan
AU - Ramamurthy, Uma
AU - Ramanathan, Vivek
AU - Rehm, Heidi L.
AU - Roumiantsev, Sergei
AU - Schwartz, Talia S.
AU - Truong, Tina K.
AU - VanNoy, Grace E.
AU - Waisbren, Susan E.
AU - Yu, Timothy W.
N1 - Funding Information:
This work was supported by grants U19-HD077671 (RG and AB) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and National Human Genome Research Institute of the NIH, and U01-TR003201 (RG and IH) from the National Center for Advancing Translational Sciences. RG was also supported by NIH grants R01-HG009922, OT2-OD026553, R01-HL143295. KC was supported by NIH grants K01-HG009173 and R01-HD090019. HS was supported by NIH grant K99-HG011491.
Publisher Copyright:
Copyright © 2022 Armstrong, Christensen, Genetti, Parad, Robinson, Blout Zawatsky, Zettler, Beggs, Holm, Green, McGuire, Smith and Pereira.
PY - 2022/4/27
Y1 - 2022/4/27
N2 - Introduction: With increasing utility and decreasing cost of genomic sequencing, augmentation of standard newborn screening (NBS) programs with newborn genomic sequencing (nGS) has been proposed. Before nGS can be integrated into newborn screening, parents’ perspectives must be better understood. Objective: Using data from surveys administered to parents of healthy newborns who were enrolled in the BabySeq Project, a randomized clinical trial of nGS alongside NBS, this paper reports parents’ attitudes regarding population-based NBS and nGS assessed 3 months after results disclosure. Methods: Parental attitudes regarding whether all newborns should receive, and whether informed consent should be required for, NBS and nGS, as well as whether nGS should be mandated were assessed using 5-point scales from strongly disagree (=1) to strongly agree (=5). Parents’ interest in receiving types of results from nGS was assessed on a 5-point scale from not at all interested (=1) to very interested (=5). Survey responses were analyzed using Fisher’s exact tests, paired t-tests, and repeated measures ANOVA. Results: At 3 months post-disclosure, 248 parents of 174 healthy newborns submitted a survey. Support for every newborn receiving standard NBS (mean 4.67) was higher than that for every newborn receiving nGS (mean 3.60; p < 0.001). Support for required informed consent for NBS (mean 3.44) was lower than that for nGS (mean 4.27, p < 0.001). Parents’ attitudes toward NBS and nGS were not significantly associated with self-reported political orientation. If hypothetically receiving nGS outside of the BabySeq Project, most parents reported being very interested in receiving information on their baby’s risk of developing a disease in childhood that can be prevented, treated, or cured (86.8%) and their risk of developing a disease during adulthood that can be prevented, treated, or cured (84.6%). Discussion: Parents’ opinions are crucial to inform design and delivery of public health programs, as the success of the program hinges on parents’ trust and participation. To accommodate parents’ preferences without affecting the current high participation rates in NBS, an optional add-on consent to nGS in addition to NBS may be a feasible approach. Trial Registration ClinicalTrials.gov Identifier: NCT02422511.
AB - Introduction: With increasing utility and decreasing cost of genomic sequencing, augmentation of standard newborn screening (NBS) programs with newborn genomic sequencing (nGS) has been proposed. Before nGS can be integrated into newborn screening, parents’ perspectives must be better understood. Objective: Using data from surveys administered to parents of healthy newborns who were enrolled in the BabySeq Project, a randomized clinical trial of nGS alongside NBS, this paper reports parents’ attitudes regarding population-based NBS and nGS assessed 3 months after results disclosure. Methods: Parental attitudes regarding whether all newborns should receive, and whether informed consent should be required for, NBS and nGS, as well as whether nGS should be mandated were assessed using 5-point scales from strongly disagree (=1) to strongly agree (=5). Parents’ interest in receiving types of results from nGS was assessed on a 5-point scale from not at all interested (=1) to very interested (=5). Survey responses were analyzed using Fisher’s exact tests, paired t-tests, and repeated measures ANOVA. Results: At 3 months post-disclosure, 248 parents of 174 healthy newborns submitted a survey. Support for every newborn receiving standard NBS (mean 4.67) was higher than that for every newborn receiving nGS (mean 3.60; p < 0.001). Support for required informed consent for NBS (mean 3.44) was lower than that for nGS (mean 4.27, p < 0.001). Parents’ attitudes toward NBS and nGS were not significantly associated with self-reported political orientation. If hypothetically receiving nGS outside of the BabySeq Project, most parents reported being very interested in receiving information on their baby’s risk of developing a disease in childhood that can be prevented, treated, or cured (86.8%) and their risk of developing a disease during adulthood that can be prevented, treated, or cured (84.6%). Discussion: Parents’ opinions are crucial to inform design and delivery of public health programs, as the success of the program hinges on parents’ trust and participation. To accommodate parents’ preferences without affecting the current high participation rates in NBS, an optional add-on consent to nGS in addition to NBS may be a feasible approach. Trial Registration ClinicalTrials.gov Identifier: NCT02422511.
KW - ELSI
KW - ethics
KW - exome sequencing
KW - genomic sequencing
KW - newborn genomic sequencing
KW - newborn screening (NBS)
KW - newborn sequencing
UR - http://www.scopus.com/inward/record.url?scp=85131898411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131898411&partnerID=8YFLogxK
U2 - 10.3389/fgene.2022.867371
DO - 10.3389/fgene.2022.867371
M3 - Article
AN - SCOPUS:85131898411
SN - 1664-8021
VL - 13
JO - Frontiers in Genetics
JF - Frontiers in Genetics
M1 - 867371
ER -